Associations of elevated Interleukin-6 and C-Reactive protein levels with mortality in the elderly∗


      PURPOSE: To investigate whether interleukin-6 and C-reactive protein levels predict all-cause and cause-specific mortality in a population-based sample of nondisabled older people.
      SUBJECTS AND METHODS: A sample of 1,293 healthy, nondisabled participants in the Iowa 65+ Rural Health Study was followed prospectively for a mean of 4.6 years. Plasma interleukin-6 and C-reactive protein levels were measured in specimens obtained from 1987 to 1989.
      RESULTS: Higher interleukin-6 levels were associated with a twofold greater risk of death [relative risk (RR) for the highest quartile (≥3.19 pg/mL) compared with the lowest quartile of 1.9 [95% confidence interval, CI, 1.2 to 3.1]). Higher C-reactive protein levels (≥2.78 mg/L) were also associated with increased risk (RR = 1.6; CI, 1.0 to 2.6). Subjects with elevation of both interleukin-6 and C-reactive protein levels were 2.6 times more likely (CI, 1.6 to 4.3) to die during follow-up than those with low levels of both measurements. Similar results were found for cardiovascular and noncardiovascular causes of death, as well as when subjects were stratified by sex, smoking status, and prior cardiovascular disease, and for both early (<2.3 years) and later follow-up. Results were independent of age, sex, body mass index, and history of smoking, diabetes, and cardiovascular disease, as well as known indicators of inflammation including fibrinogen and albumin levels and white blood cell count.
      CONCLUSIONS: Higher circulating levels of interleukin-6 and C-reactive protein were associated with mortality in this population-based sample of healthy older persons. These measures may be useful for identification of high-risk subgroups for anti-inflammatory interventions.
      To read this article in full you will need to make a payment


        • Liuzzo G
        • Biasucci L.M
        • Gallimore J.R
        • et al.
        The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina.
        NEJM. 1994; 331: 417-424
        • Haverkate F
        • Thompson S.G
        • Pyke S.D.M
        • Gallimore J.R
        • Pepys M.B
        • European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
        Production of C-reactive protein and risk of coronary events in stable and unstable angina.
        Lancet. 1997; 349: 462-466
        • Ridker P.M
        • Cushman M
        • Stampfer M.J
        • Tracy R.P
        • Hennekens C.H
        Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
        NEJM. 1997; 336: 973-979
        • Kuller L.H
        • Tracy R.P
        • Shaten J
        • Meilahn E.N
        • MRFIT Research Group
        Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study.
        Am J Epidemiol. 1996; 144: 537-547
        • Tracy R.P
        • Lemaitre R.N
        • Psaty B.M
        • et al.
        Relationship of C-reactive protein to risk of cardiovascular disease in the elderly.
        Arterioscler Throm Vasc Biol. 1997; 17: 1121-1127
        • Thompson S.G
        • Kienast J
        • Puke S.D.M
        • Haverkate F
        • van de Loo J.C
        Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
        NEJM. 1995; 332: 635-641
        • Vallance P
        • Collier J
        • Bhagat K
        Infection, inflammation, and infarction.
        Lancet. 1997; 349: 1391-1392
        • Pelliniemi T.T
        • Irjala K
        • Mattila K
        • et al.
        • Finnish Leukemia Group
        Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma.
        Blood. 1995; 85: 765-771
        • Moreland L.W
        • Baumgartner S.W
        • Schiff M.H
        • et al.
        Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
        NEJM. 1997; 337: 141-147
        • Jilka R.L
        • Hangroc G
        • Girasole G
        • et al.
        Increased osteoclast development after estrogen loss.
        Science. 1992; 257: 88-91
        • Torre-Amione G
        • Kapadia S
        • Benedict C
        • Oral H
        • Young J.B
        • Mann D.L
        Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction.
        J Am Coll Cardiol. 1996; 27: 1201-1206
        • Pannen B.H.J
        • Robotham J.L
        The acute-phase response.
        New Horizons. 1995; 3: 183-197
        • Gauldie J
        • Richards C
        • Northemann W
        • Fey G
        • Baumann H
        IFNB2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes.
        Ann NY Acad Sci. 1989; 557: 46-59
        • Kushner I
        • Jiang S.L
        • Zhang D
        • Lozanski G
        • Samols D
        Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1?.
        Ann NY Acad Sci. 1995; 762: 102-107
        • Mestries C
        • Kruithof E.K.O
        • Gascon M.P
        • Herodin F
        • Agay D
        • Ythier A
        In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons.
        Eur Cytokine Network. 1994; 5: 273-281
        • Bataille R
        • Klein B
        C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo.
        Arthritis Rheum. 1992; 35: 982-983
        • Lu Z.Y
        • Brailly H
        • Wijdenes J
        • Bataille R
        • Rossi J.F
        • Klein B
        Measurement of whole body interleukin-6 (IL-6) production.
        Blood. 1995; 86: 3123-3131
        • Cornoni-Huntley J
        • Ostfeld A.M
        • Taylor J.A
        • et al.
        Established populations for epidemiologic studies of the elderly.
        Aging. 1993; 5: 27-37
        • Macy E.M
        • Hayes T.E
        • Tracy R.P
        Variability in the measurement of C-reactive protein in healthy subjects.
        Clin Chem. 1997; 43: 52-58
        • Geffken D
        • Keating F
        • Kennedy M
        • Cornell E
        • Bovill E
        • Tracy R
        The measurement of fibrinogen in population-based research.
        Arch Pathol Lab Med. 1994; 118: 1106-1109
      1. Preston DL, Lubin JH, Pierce DA, McConney ME. Epicure User’s Guide. Seattle, WA: HiroSoft International Corporation, 1993.

        • Prentice R.L
        A case-cohort design for epidemiologic cohort studies and disease prevention trials.
        Biometrika. 1986; 73: 1-11
        • Papanicolaou D.A
        The pathophysiologic roles of interleukin-6 in human disease.
        Ann Intern Med. 1998; 128: 127-137
        • Van der Poll T
        • Levi M
        • Hack C.E
        • et al.
        Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.
        J Exp Med. 1994; 179: 1253-1259
        • Cermak J
        • Key N.S
        • Bach R.R
        • Balla J
        • Jacob H.S
        • Vercellotti G.M
        C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.
        Blood. 1993; 82: 513-520
        • Cohen H.J
        • Pieper C.F
        • Harris T.B
        • Rao K.M.K
        • Currie M.S
        The association of plasma IL-6 levels with functional disability in community-dwelling elderly.
        J Gerontol Med Sci. 1997; 52A: M201-M208
        • Danesh J
        • Collins R
        • Peto R
        Chronic infections and coronary heart disease.
        Lancet. 1997; 350: 430-436
        • Baeuerle P.A
        • Rupec R.A
        • Pahl H.L
        Reactive oxygen intermediates as second messengers of a general pathogen response.
        Path Biol. 1996; 44: 29-35
        • Tilg H
        • Dinarello C.A
        • Mier J.W
        IL-6 and APPs.
        Immun Today. 1997; 18: 428-432
        • Xing A
        • Gauldie J
        • Cox G
        • et al.
        IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory response.
        J Clin Invest. 1998; 101: 311-320
        • Van Zaanen HC
        • Koopmans R.P
        • Aarden L.A
        • et al.
        Endogenous interleukin-6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
        J Clin Invest. 1996; 98: 1141-1148
        • DeRijk R
        • Michelson D
        • Karp B
        • et al.
        Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1, IL-6 and tumor necrosis factor-production in humans.
        J Clin Endocrinol Metab. 1997; 87: 2182-2191
        • Sothern R.B
        • Roitman-Johnson B
        • Kanabrocki E.L
        • et al.
        Circadian characteristics of IL-6 in blood and urine of clinically healthy men.
        In Vivo. 1995; 9: 331-339
        • Rao K.M.K
        • Pieper C.S
        • Currie M.S
        • Cohen H.J
        Variability of plasma IL-6 and crosslinked fibrin dimers over time in community-dwelling elderly subjects.
        Am J Clin Pathol. 1994; 102: 802-805
        • Mendenhall M.A
        • Patel P
        • Ballam L
        • Strachan D
        • Northfield T.C
        C reactive protein and its relationship to cardiovascular risk factors.
        BMJ. 1996; 312: 1061-1065
        • Tracy R.P
        • Macy E.M
        • Bovill E.G
        • et al.
        Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects.
        Arterioscler Thromb Vasc Biol. 1997; 17: 2167-2176